Co-leader, Immunology Program, UNC Lineberger Comprehensive Cancer Center
Area of Interest
Gianpietro Dotti, MD, is a research professor of microbiology and immunology at UNC and director of the Lineberger Comprehensive Cancer Center Immunotherapy Program. Dotti received his medical degree at the University of Milan in Milan, Italy, in 1989 with subsequent clinical training and board certification in hematology at the University of Parma in Parma, Italy, in 1995. From 1996 to 1999, he completed a research fellowship in molecular biology at Ospedali Riuniti di Bergamo in Bergamo, Italy, where he developed technologies to detect minimal residual disease in hematological malignancies and studied molecular mechanisms of post-transplant lymphomas. He completed a postdoctoral fellowship in translation research at the Center for Cell and Gene Therapy at the Baylor College of Medicine in Houston, Texas.
In 2002, he joined the Center for Cell and Gene Therapy at Baylor initially as an instructor and then ranking all the academic positions up to professor with tenure in 2014. It was there that Dotti studied immunotherapy strategies to treat patients with hematologic malignancies including lymphomas and leukemia. In particular, he developed the program of the CD19-specific chimeric antigen receptor in that institution and cloned a novel chimeric antigen receptor targeting the light chain of human immunoglobulins. Dotti was also involved in developing CAR-based strategies to target neuroblastoma in pediatric patients. In collaboration with Brenner he also developed the clinical phase of a novel safety switch for T-cells based on the human caspase-9. Dotti is continuing his research at UNC with particular interest in developing CAR-T cells for the treatment of solid tumors.
News and Stories
UNC Lineberger pancreatic cancer therapy studies backed by 5-year, $10.9 million NIH SPORE grant
The National Cancer Institute has awarded the UNC Lineberger Pancreatic Cancer Center of Excellence a five-year, $10.9 million Pancreatic Cancer Specialized Program of Research Excellence (SPORE) grant.
Implant churns out CAR-T cells to combat cancer in animal models
Yevgeny Brudno, PhD, and colleagues from NC State University and UNC-Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T for attacking cancerous tumors.
UNC Lineberger faculty recognized as being among the world’s most influential researchers
Fifteen UNC Lineberger Comprehensive Cancer Center members were named as 2021 Highly Cited Researchers by Clarivate for publishing some of the most influential scientific papers during the past decade.
Gel enhances CAR-T immunotherapy benefits in brains surgically treated for glioblastoma
Researchers from UNC Lineberger and colleagues report pairing a newly developed gel with immunotherapy that was delivered to post-surgical lab models with glioblastoma improved the immunotherapy’s effectiveness.